` Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Tam Constantine S.; Opat Stephen; Cull Gavin; Trotman Judith; Gottlieb David; Simpson David; Marlton Paula; Anderson Mary Ann; Ku Matthew; Ritchie David; Ratnasingam Sumita; Augustson Bradley; Kirschbaum Mark; Wang Lai; Xue Ling; Yang Jianxin; Hedrick Eric; Seymour John F.; Roberts Andrew W.

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >` Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

【24h】

` Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

机译：每天两次用高度特异性的BTK抑制剂Bgb-3111给药，在淋巴结中达到完全和连续的BTK占有率，并与慢性淋巴细胞性白血病（CLL）/小淋巴细胞性淋巴瘤（SLL）患者的持久反应相关

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共7页
作者
Tam Constantine S.; Opat Stephen; Cull Gavin; Trotman Judith; Gottlieb David; Simpson David; Marlton Paula; Anderson Mary Ann; Ku Matthew; Ritchie David; Ratnasingam Sumita; Augustson Bradley; Kirschbaum Mark; Wang Lai; Xue Ling; Yang Jianxin; Hedrick Eric; Seymour John F.; Roberts Andrew W.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
专利

1. ` Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [J] . Tam Constantine S., Opat Stephen, Cull Gavin, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：每天两次用高度特异性的BTK抑制剂Bgb-3111给药，在淋巴结中达到完全和连续的BTK占有率，并与慢性淋巴细胞性白血病（CLL）/小淋巴细胞性淋巴瘤（SLL）患者的持久反应相关
2. Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo [J] . McClanahan Fabienne, Reiff Sean D., Guinn Daphne, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：探索超越慢性淋巴细胞白血病（CLL）细胞的BTK的功能相关性：微环境的非恶性免疫细胞中的BTK表达介导CLL体内发育。
3. Exploring the Functional Relevance of BTK Beyond Chronic Lymphocytic Leukemia (CLL) Cells: BTK Expression in Non-Malignant Immune Cells of the Microenvironment Mediates CLL Development and Progression In Vivo [J] . McClanahan Fabienne, Reiff Sean D., Guinn Daphne, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：探索超越慢性淋巴细胞白血病（CLL）细胞的BTK的功能相关性：微环境的非恶性免疫细胞中的BTK表达介导CLL体内发育。
4. Proteomics-based target deconvolution of clinical multi-kinase inhibitors inducing apoptosis in primary chronic lymphocytic leukemia cells (CLL) [C] . Marcus Bantscheff, Ulrich Kruse, Christian P. Pallasch, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2010

机译：基于蛋白质组学的临床多激酶抑制剂诱导肾凋亡凋亡的靶碎屑（CLL）
5. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2 single-arm multicenter study [O] . Wei Xu, Shenmiao Yang, Keshu Zhou, 2020

机译：使用BTK抑制剂zanubrutinib治疗复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤：2期单臂多中心研究
6. SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) [O] . C.S. Tam, H. Quach, A. Nicol, 2017

机译：高度特异性BTK抑制剂，BGB-3111加上患者（PTS）的安全性和活性，卵泡淋巴瘤（FL）和慢性淋巴细胞白血病（CLL）

` Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

著录项

相似文献

相关主题

期刊订阅